FDA expands approval for GSK’s RSV vaccine to cover younger at-risk adults
Posted:
The Food and Drug Administration expanded the approval for GSK’s vaccine to protect against respiratory syncytial virus, or RSV, authorizing its use for at-risk adults as young as 50.
Researchers at the Ribeirão Preto Blood Center and the Center for Cell-Based Therapy (CTC) are exploring a key question in cancer immunotherapy: how to “wire” engineered natural killer (NK) cells so they respond faster and hit harder when they encounter…
SMARTWATCH screening has been shown to significantly improve atrial fibrillation detection in older, high-risk patients, with researchers reporting substantially higher diagnosis rates compared with standard care.
Read more here.
Attendees
Sponsors and Exhibitors
Contact us